SOURCE: Market Pulse

March 07, 2006 08:50 ET

Market Pulse Breaking News Alert for Tuesday, March 7, 2006: DNAG -- DNAPrint Genomics Scientist to Co-Chair Discussion on "Genetic Testing" at the American Association of Physical

Anthropologists Annual Meeting!

ATLANTA, GA, -- (MARKET WIRE) -- March 7, 2006 -- Market Pulse News Alert for this AM, Stocks to Watch are: DNAPrint Genomics, Inc. (OTC BB: DNAG), Ivanhoe Energy Inc. (NASDAQ: IVAN), Finisar Corp. (NASDAQ: FNSR) and Quest Communications International Inc. (NYSE: Q).

Investors need to be watching DNAPrint Genomics, Inc. (OTC BB: DNAG) this AM! DNAPrint is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology, and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness™, RETINOME™ (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA™, and EURO-DNA™. DNAPrint's management sees exciting growth opportunity in these markets to introduce and sell their novel products and services. DNAG has had several excellent news announcements out lately and one again before today's opening bell announcing that their scientist Dr. Ripan Malhi will co-chair a discussion on genetic testing at the American Association of Physical Anthropologists annual meeting! Investors should be watching this one closely!

DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that Dr. Ripan Malhi will co-chair a symposium of 14 scientists and business persons for a discussion of ethical and sociopolitical issues surrounding consumer genetic testing as part of the 75th annual meeting of the American Association of Physical Anthropologists in Anchorage, Alaska. Dr. Malhi is the Senior Research Director of Trace Genetics, Inc., the Company's wholly owned subsidiary. The four-day meeting, which begins Wednesday, March 8, features several symposiums and poster discussions. This symposium focuses on the interpretation of genetic test results and the public's understanding of race, ethnicity, human genetic variation and evolutionary history of the human species.

"The purpose of this symposium is to have a rigorous discussion of lineage based and whole genome tests exploring the anthropological, biomedical, and societal applications of genetic ancestry testing," explains Dr. Malhi. "It should be a lively discussion. We have purposefully brought together competent spokespersons with diverse perspectives. This will be an opportunity for opinions to be expressed and challenged and, ideally, allow the group as a whole to resolve issues in a direct and productive manner."

The symposium brings together scientists and experts from academia and private enterprise in an effort to build a consensus about how the public might best use genetic testing to understand their own ancestry within a valid scientific framework. Recent television specials and news publications have spurred public interest in genetic testing, resulting in the recent purchase by consumers of more than 150,000 genetic ancestry tests. The popularity of these genetic tests reflects a widespread interest by the public in using DNA technology to learn about family ancestry. Many anthropologists are concerned that the interpretation of the results of these tests may not give a complete and accurate picture of an individual's personal genetic history.

"Until recently the only way genealogists could determine their ancestors' origins was through records and oral history that traced ancestors as far back as the documentation existed. Now, genetic tests can reveal remote anthropological ancestry and suggest proportions of various ethnic and geographical origins such as Native American ancestry, in a given person's heritage. Genealogists should use the information for the test's intended purpose as one piece of a large and complex puzzle and avoid prejudice based on what they hoped they would find," commented Dr. Tony Frudakis, Chief Scientific Officer for DNAPrint Genomics.

The symposium is a featured event of the annual meeting, and is scheduled to be the cover article of the Saturday, March 11, edition of New Scientist magazine.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. ( is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre--trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Stocks in the news and acting well as of late include: Ivanhoe Energy Inc. (NASDAQ: IVAN), Finisar Corp. (NASDAQ: FNSR) and Quest Communications International Inc. (NYSE: Q).

Information contained herein is the opinion of ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis.

Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated two hundred twenty five thousand dollars from DNAPrint Genomics, Inc. MP was also compensated six million restricted shares of common stock directly from DNAPrint Genomics, Inc. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information